Suggested remit: To appraise the clinical and cost effectiveness of belzutifan within its marketing authorisation for untreated clear-cell renal cell carcinoma caused by von Hippel-Lindau disease.
Status In progress
Process STA 2018
ID number 3932

Provisional Schedule

Expected publication 17 August 2022

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
10 June 2021 - 08 July 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
26 May 2021 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during late September 2021 when we will write to you about how you can get involved. These timelines are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
23 November 2020 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance